sensitivity in our hands) in bone marrow samples from 13 CML patients: two patients at diagnosis and 11 patients in hematological remission after alpha interferon (three patients), hydroxyurea (one patient) autologous bone marrow transplantation (BMT) (one patient) and allogeneic BMT (six patients). In the two diagnostic patients, 90 and 95% cells were respectively strongly positive by in situ RT-PCR. In the six patients treated by allogeneic BMT, the median percentage of positive cells was 2.4% (range 1.8-3.2). All six patients had normal karyotype and negative two-step RT-PCR results. In the five other patients, two were treated by hydroxyurea alone or autologous BMT, and 11 and 13% of the cells were strongly positive; three were treated with interferon and 14-62% of the cells were positive, generally weakly. All five patients had persistence of Ph1 (in 9-56% mitoses), and positive RT-PCR results after one round. In conclusion, in situ RT-PCR can specifically identify cells with BCR-ABL transcript and its results are concordant with those of karyotype and RT-PCR. Because of its limited sensitivity and specificity, however, it appears to have limited value in the analysis of MRD. On the other hand, it can evaluate the presence and intensity of BCR-ABL fusion transcript at the single cell level, and this could be useful in treatment monitoring.
Introduction

Chronic myelogenous leukemia (CML) is characterized by a
Correspondence: P Fenaux, Service des Maladies du Sang, Hô pital Huriez 59037 Lille, France Received 13 July 1998; accepted 21 January 1999 t(9;22) translocation (Philadelphia (Ph1) chromosome) that fuses BCR and ABL genes. [1] [2] [3] [4] The resultant fusion mRNA is a molecular marker that allows diagnosis of CML and followup of minimal residual disease (MRD) after bone marrow transplantation (BMT) or interferon ␣ (IFN␣) treatment. [5] [6] [7] [8] [9] For the detection of MRD, conventional cytogenetics and Southern blotting have low sensitivity (1-5%), and reverse transcriptase polymerase chain reaction (RT-PCR) has a very high sensitivity (10 −6 after two rounds in our hands). 9 Fluorescent in situ hybridization (FISH) allows detection of the BCR-ABL fusion gene but can usually only be performed on metaphase or interphase cytogenetic cell preparations, and has relatively low sensitivity (5% in our hands). 10, 11 In this work, we have developed a technique of in situ RT-PCR for the detection of BCR-ABL transcript on blood and bone marrow smears from CML patients at different disease stages and compared it with cytogenetic and RT-PCR analysis.
Patients and methods
Controls
In order to assess the specificity and sensitivity of the in situ RT-PCR technique, two positive cell lines with BCR-ABL fusion (K562, BV173), two negative cell lines (U937, HL60) and five normal subjects were tested. Cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA).
Patients
After obtaining informed consent, 13 CML patients, including two patients at diagnosis and 11 patients in hematological remission were studied (Table 1) . Three patients had been treated with IFN for 17-32 months, one patient had been treated with hydroxyurea for 20 months, one had received an autologous BMT. None of those five patients were in cytogenetic CR. Six had received an allogeneic BMT. All were in cytogenetic CR.
Cytogenetic analysis
Cytogenetic analysis was performed on bone marrow cells after 24 h in vitro culture without stimulation. Chromosomes 819  Table 1 List, name and localization of primers used were identified by RHG and GTG banding. At least 50 metaphases were analyzed before concluding the absence of Ph1 chromosome.
RT-PCR analysis
RT-PCR analysis was performed on RNA obtained from bone marrow samples. cDNA preparation and DNA amplification of BCR-ABL and ABL transcripts were performed as previously published.
9,12
In situ RT-PCR analysis
Cell preparation: Bone marrow mononuclear cells were separated and isolated by centrifugation on Ficoll-Hypaque gradient. Cells were washed twice in phosphate-buffered saline (PBS) pH 7.4 and 50 × 10 3 cells were centrifuged at 700 r.p.m. for 5 min on slides treated with poly-l-lysine Superfrost (CML, Nemours, France). Cells were fixed in a 4% paraformaldehyde (PFA) solution for 10 min at room temperature. After fixation, they were rehydrated with SSC × 0.2 for 10 min at room temperature. Cells were then digested by proteinase K (10 g/ml) for 10 min at 37°C. Slides were rinsed in PBS pH 7.4 for 5 min at 80°C.
Reverse transcription:
A total of 38 l of a reaction mixture containing 400 U of MMLV reverse transcriptase (Life Technologies, Cergy Pontoise, France), 2 l of hexanucleotides at 20 pm (Pharmacia, Uppsala, Sweden), 50 mm Tris HCl pH 8.3, 6 mm MgCl 2 , 40 mm HCl, 1 mm dithiothreitol, 1 mg/ml bovine serum albumine, 2.5 mm each dNTP was deposited on the slides. The slides were coverslipped and incubated for 2 h on an in situ RT-PCR automated GENE E apparatus (Techne, Cambridge, UK).
After retro transcription, the slides were washed in PBS pH 7.4 for 2 min at room temperature, post fixed with PFA 0.4% for 20 min at 4°C, then washed twice in PBS pH 7.4 for 5 min at room temperature, and finally dehydrated in an ice-cold ethanol series (70.85 and 100%).
In situ DNA amplification:
25 l of a final mixture containing 50 mm dATP, 50 mm dCTP, 50 mm dGTP, 45 mm dTTP and 5 mm dig 11 dUTP, 20 mm Tris HCl pH 8.6, 2 mm MgCl 2 , 50 mm KCl, 20 pmoles of each primer and 2.5 U Taq polymerase (Boehringer, Mannheim, Germany) was deposited in a chamber (OSI, Maurepas France), according to the recommandations of Nuovo, 13 and sealed on fixed slides previously heated for 2 min at 94°C. Amplification on the in situ automated thermocycler was started by 2 min of denaturation, then 20 cycles with a 94°C denaturation step of 1 min and an elongation step at 72°C for 2 min, followed by a final elongation at 72°C for 5 min. For each sample, two amplifications were performed using primers A1, A3, A4 for ABL and A1, B1 for BCR-ABL, respectively 9 (see Table 1 ). After amplification, the slides were washed at 60°C in a stop solution (50 mm NaCl, 50 mm EDTA, PH 8), then three times for 5 min at 37°C in a solution containing 0.2% Tween-20 diluted in PBS. Finally, the slides were rinsed for 1 min at 37°C in PBS. The PCR product was then revealed by incubation of the slide for 30 min at 37°C in the dark in a coplin jar containing FITC digoxigenin antibody (Boehringer). The slides were then washed three times in the Tween solution and once in PBS at 37°C. Finally, they were briefly dehydrated through ethanol series, air dried and mounted with Vectashield antifading medium (Vector Laboratories, Burlingame, CA, USA) containing 4,6-diamino, 2-phenylindole dihydrochloride (DAPI; 0.2 g/ml final concentration). Slides were scored by two different observers using an epifluorescent axioscope microscope (Zeiss, Oberkochen Germany). For each slide, each observer scored 500 nuclei.
Results
All results are summarized in Table 2 .
Cytogenetic and RT-PCR results
The six allografted patients had normal karyotype and tworound RT-PCR negative results. The other seven patients (including the two patients studied at diagnosis and the five patients treated with other modalities) had 9-100% positive Ph1 metaphases, and positive RT-PCR results after one round.
In situ RT-PCR results
Positive and negative controls:
Using BCR-ABL primers, a strong positive green signal was observed in a median of 98% (97-99) and 99% (98-100%) cells of BV173 and K562 cell lines, respectively. The positive signal was even stronger with K562 because this cell line has BCR-ABL gene amplification and duplication of Ph1 chromosome 14 ( Figure 1 ). A faint signal was detected in 1.5% and 2% of U937 and HL60 negative cell lines, respectively. In the five normal sub- jects, 1.6-2.8% of the cells were faintly positive (mean 2.2 ± 1.1). The positive threshold for in situ RT-PCR, determined as mean + 2 standard deviations, was therefore considered to be 4.4% cells. The specificity of the signal observed with K562 and BV173 cell lines was confirmed using several controls: one with RNase treatment and four without hexanucleotides, reverse transcriptase, specific primers and Taq polymerase, respectively. No signal was detected in any of those controls ( Figure  1) . Quality of the RNA was confirmed by amplification of the ABL transcript. All slides had a positive green signal in more than 97% of the cells.
Results in CML patients:
In the two patients studied at diagnosis (Nos 1 and 2), 90 and 95% cells were strongly positive by in situ RT-PCR, confirming conventional cytogenetic results ( Table 2 ). The intensity of the signal was comparable to that of the BV173 cell line.
In the six patients treated by allogeneic BMT (Nos 3-8), 1.8-3.2% of faintly positive cells was observed. In patients 9 and 10, treated with hydroxyurea and autologous BMT, respectively, 11 and 13% of the cells were positive, most of them strongly. In the three remaining patients treated with interferon, 14-62% cells were positive by in situ RT-PCR, but staining was generally weak. All the slides had a positive signal with ABL primers, confirming the quality of RNA. After amplification, 3 l of the supernatant was amplified with the A2, B2 nested primers according to the conditions previously described. 9, 12 The PCR product amplification was analyzed on 2% agarose gel staining with ethidium bromide. As seen in Figure 2d , the results were similar to the results obtained by nested PCR performed on the total RNA from the same patient. The size of the PCR product was 301 bp or 226 bp, respectively, for b3a2 or b2a2 transcripts.
Discussion
In situ PCR is a new technique which has been applied successfully for the analysis of genomic DNA of human papillomavirus, HIV virus and lentiviruses. [15] [16] [17] However, few studies of in situ PCR have been performed on mRNA in hematological malignancies. 18, 19 In the paper of Testoni et al, in situ RT-PCR, called by the authors 'in-cell' RT-PCR, was performed in cell suspensions and analyzed by flow cytometry in 10 CML patients, including four at diagnosis, two after interferon therapy, and four after allogeneic BMT. In situ RT-PCR proved more sensitive than conventional cytogenetics and equally as sensitive as RT-PCR in detecting Ph1 positive cells.
Our technique is somewhat different in that it is performed on blood or marrow slides. Indeed, in our center, we routinely freeze blood and marrow slides at diagnosis and during evolution in leukemia patients. These slides can also be used for immunocytochemical studies of various cellular proteins at the single cell level, for example for immunophenotyping. In order to perform the in situ RT-PCR technique directly on slides, small incubation chambers were used after the retrotranscription stage. This prevented dehydration during subsequent PCR amplification. Like Testoni et al, 18 we found that proteinase K digestion was required after the fixation stage by paraformaldehyde. This digestion greatly improved cell permeabilization. However, contrary to Testoni et al, who performed PCR with fluorescent primers, we used an indirect However they examined only three normal subjects, only 100-150 cells in each case, and no negative cell lines were tested.
In our study, the intensity of the cell signal was variable depending on the disease stage and treatment. In the two patients studied at diagnosis, the BCR-ABL signal was strong in all positive cells. In patients treated with allogeneic BMT, the few positive cells all had a faint signal, identical to that observed in negative controls, suggesting that this corresponded to background activity. In patients treated with interferon, 14-62% of the cells were positive. However, in most positive cells BCR-ABL signal was fainter than in diagnosis samples. On the other hand, in the two patients treated with hydroxyurea or autologous BMT, 11 and 13% cells, respectively, were positive and generally showed a strong BCR-ABL signal. Finally, even in the two diagnosis samples, 5-10% of the cells did not express BCR-ABL transcript. Whether or not these cells were truly Ph1 negative non-clonal cells cannot be ascertained.
In the present study, in situ RT-PCR gave concordant results with karyotype and RT-PCR for diagnosis in CML samples, positive and negative cell lines, and normal subjects. Therefore, in situ RT-PCR may help in the diagnosis of CML when RT-PCR and karyotype are unavailable. Because the positivity threshold of in situ RT-PCR was estimated at 4.4%, in our hands, low sensitivity of this test in the detection of minimal residual disease in CML could be anticipated. Indeed, in treated CML patients, in situ RT-PCR results were not more sensitive than those of cytogenetics when a sufficient number of mitoses was examined by this technique. Furthermore, results of in situ RT-PCR were clearly inferior to those of RT-PCR which can detect, in our hands, one leukemic cell expressing BCR-ABL in 10 6 cells. 9 This was different from the results of Testoni et al, who considered in situ RT-PCR to be a sensitive method of minimal residual disease assessment in CML. The main reason for this difference, as seen above, was the presence of a small percentage of weakly stained cells in all our controls, contrary to the experience of Testoni et al. On the other hand, the interest of the in situ RT-PCR techniques is that it allows identification of the cells that express the fusion transcript, and differentiate them from cells that do not express it, and are presumably non-clonal. Finally, this technique may also be applicable to other hematological malignancies with fusion transcripts.
